Opinion

Video

Insights from the TROPION-Lung05 Trial at ASCO 2024

Jason Porter, MD, analyzes the TROPION-Lung05 trial investigating Dato-DXd in non-small cell lung cancer patients with brain metastases, emphasizing crucial insights from this pivotal study.

Video content above is prompted by the following questions:

  1. Discuss the data that was presented at the ASCO 2024 on intracranial overall response rate in the TROPION-Lung05 trial with Dato-DXd in patients with brain metastasis from NSCLC.
  2. What are your key takeaways from this study and how will this impact the treatment of patients with brain metastasis from NSCLC?
Related Videos
Divya Gupta, MD
Divya Gupta, MD
Ticiana Leal, MD
Joshua K. Sabari, MD, NYU Langone Perlmutter Cancer Center
Ana Baramidze, MD, PhD
Ticiana Leal, MD, Emory Winship Cancer Institute
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
Jason Porter, MD, an expert on lung cancer
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo